Antidepressant therapy: new targets for drug development

Bibliography

• PERRY PJ: Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J .Affect. Disord. (1998) 39:1–6.
   Google Scholar
• ••Review of the efficacy of tricyclic and SSRIantidepressants, with special attention to the possible limitations to the effects of the latter in mote severe depression.
   Google Scholar
• OWENS MJ, MORGAN WN, PLOTT SJ, NEMEROFF CB: Neurotransmitter receptor and transporter binding profile ofantidepressants and their metabolites. JPET(1997) 283:1305–1322.
   PubMed Web of Science ®Google Scholar
• ••Landmark paper contrasting the affinitiesof antidepressants at a variety of binding sites, using several cell model systems.
   Google Scholar
• RICHELSON E: Synaptic effects of antidepressants. J. CM]. Psychopharmacol(1996) 16\(Suppl. 2):1S–9S.
   Google Scholar
• SIMON GE, VONKORFF M. HEILIGENSTEIN JH et al: Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine versus tricyclic antidepressants. JAMA. (1996) 275(24):1897–902.
   Google Scholar
• SIMON GE, HEILIGENSTEIN J, REVICKI D et al.: Long-term outcomes of initial antidepressant drug choice in a 'real world' randomized trial. Arch. Fain. Med.(1999) 8(4):319–25.
   PubMedGoogle Scholar
• THOMPSON C, PEVELER RC, STEPHENSON D, MCKENDRICK J: Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am. Psychiatry157(3):338–343.
   Google Scholar
• ••This paper questions the actual advantage ofSSRI antidepressants in real world practice.
   Google Scholar
• LAUX G: Cost-benefit analysis of newer versus older antidepressants-pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants. Pharmacopsychiatry (2001) 34(1):1–5.
   PubMedGoogle Scholar
• PANZARINO PJ JR. NASH DB: Cost-effective treatment of depression with selective serotonin reuptake inhibitors. Am. Managed Care (2001) 7:173–184.
   PubMed Web of Science ®Google Scholar
• ROSEN RC. LANE RM. MENZA M: Effects of SSRIs on sexual function: a critical review. I CM]. Psychopharmacology (1999) 19(1):67–85.
   Google Scholar
• SHELTON RC. Cellular mechanisms of antidepressant drug action. Har. Rev Psychiatry (2000) 8:161–174.
   PubMed Web of Science ®Google Scholar
• ••A review of putative intracellularmechanisms of action of current antidepressant drugs.
   Google Scholar
• DELGADO PL, PRICE LH, MILLER HL: et al. Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch. Gen. Psychiatry (1994) 51:865–874.
   PubMed Web of Science ®Google Scholar
• MILLER HL, DELGADO PL, SALOMON RIVI et al.: Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch. Gen. Psychiatry (1996) 53:117–128.
   PubMed Web of Science ®Google Scholar
• BERMAN RIVI, NARASIMHAN M, MILLER HL etal.: Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch. Gen. Psychiatry (1999) 56:395–403.
   Google Scholar
• NIBUYA M, NESTLER EJ, DUMAN RS: Chronic antidepressant administration increases the depression of cAMP response element binding protein (CREB) in rat hippocampus. j Neurosci. (1996)16:2365–2372.
   PubMed Web of Science ®Google Scholar
• RUSSO-NEUSTADT A, BEARD RC, COTMAN CW: Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology (1999) 21:679–682.
   PubMed Web of Science ®Google Scholar
• PEIFFER A, VEILLEUX S, BARDEN N: Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychorreuroendocrinology (1991) 16:505–515.
   PubMed Web of Science ®Google Scholar
• ••An early description of the effects ofantidepressants in enhancing the expression of glucocorticoid receptor mRNA.
   Google Scholar
• SECKL JR, FINK G: Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology (1992) 55:621–626.
   PubMed Web of Science ®Google Scholar
• ROSSBY SP, NALEPA I, HUANG M etal.: Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res. (1995) 687:79–82.
   Google Scholar
• ROSSBY SP, MANIER DH, LIANG S: Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. Int. Neuropsychopharmacol. (1999) 2:1–8.
   PubMed Web of Science ®Google Scholar
• BRADY LS: Stress, antidepressant drugs and the locus coeruleus. Brain Res. Bull. (1994) 35:545–556
   PubMedGoogle Scholar
• BOYER PA, SKOLNICK P, FOSSOM LH: Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain: a quantitative in situ hybridization study. Mal Neurosci. (1998) 10:219–233.
   PubMed Web of Science ®Google Scholar
• GRIEBEL G: Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacy]. Ther. (1999)82:1–61.
   Google Scholar
• GOLD PW, GOODWIN FK, CHROUSOS GP: Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N Engl. Medicine. (1988) 319:348–353.
   Google Scholar
• ••Major review (along with ND postulatingdepression as a stress-system disorder.
   Google Scholar
• GOLD PW, GOODWIN FK, CHROUSOS GP: Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2). N Engl. Medicine. (1988) 319:413–420.
   PubMed Web of Science ®Google Scholar
• ••Major review (along with [23]) postulatingdepression as a stress-system disorder.
   Google Scholar
• ARBORELIUS L, OWENS MJ, PLOTSKY PM, NEMEROFF CB: The role of corticotropin-releasing factor in depression and anxiety disorders. Endocnnol. (1999) 160:1–12.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of the role of CRH indepression and anxiety.
   Google Scholar
• ZIMMERMAN M, PFOHL B, STANGL D, CORYELL W: An American validation study of the Newcastle diagnostic scale. I. Relationship with the dexamethasone suppression test. Br. I Psychiatry (1986) 149:627–630.
   Google Scholar
• PLOTSKY PM, OWENS MJ, NEMEROFF CB: Psychoneuroendocrinology of depression: hypothalamic-pituitary-adrenal axis. Psychiatric N Am. (1998) 21:293–307.
   PubMed Web of Science ®Google Scholar
• ••Review of the hypothalamic-pituitary-adrenal axis abnormalities in depression.
   Google Scholar
• NEMEROFF CB, WIDERLOV E, BISSETTE G et al.: Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 226:1342–1344.
   PubMed Web of Science ®Google Scholar
• ••Seminal paper showing elevated levels ofCRH in CSF of depressed patients, providing support for the importance of the hypothalamic-pituitary-adrenal axis abnormalties in depression.
   Google Scholar
• NEMEROFF CB, OWENS MJ, BISSETTE G, ANDORN AC, STANLEY M: Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. am Psych/at. (1988) 45:577–579.
   PubMed Web of Science ®Google Scholar
• ARATO M, BANKI CM, BISSETTE G, NEMEROFF CB: Elevated CSF CRF in suicide victims. Biol. Psychiatry (1989) 25:355–359.
   PubMed Web of Science ®Google Scholar
• BANKI CM, KARMACSI L, BISSETTE G, NEMEROFF CB: Cerebrospinal fluid neuropeptides in mood disorder and dementia. I Affective Disord. (1992) 25:39–45.
   PubMed Web of Science ®Google Scholar
• NEMEROFF CB, BISSETTE G, AKIL H, FINK M: Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy: corticotropin-releasing factor, 13-endorphin and somatostatin. Br. I Psychiatry (1991) 158:59–63.
   PubMed Web of Science ®Google Scholar
• DE BELLIS MD, GOLD PW, GERACIOTI TD Jr., LISTWAK SJ, KLING MA: Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am . Psychiatry (1993) 150:656–657.
   Google Scholar
• HOLSBOER F, VON BARDELEBEN U, BULLER R, HEUSER I, STEIGER A: Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Harm. Metab. Res. (1987) 16(Suppi.):80–88.
   Google Scholar
• MOLCHAN SE, HILL JL, MARTINEZ RA: CSF somatostatin in Alzheimers disease and major depression: Relationship to hypothalamic-pituitary-adrenal axis and 1707 Expert Op/n. Ther. Patents (2001) 11(11) clinical measures. Psychoneuroendocrinology (1993) 18:509–519.
   Google Scholar
• PITTS AF, SAMUELSON SD, MELLER WH, BISSETTE G, NEMEROFF CB, KATHOS RG: Cerebrospinal fluid corticotropin releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Biol. Psychiatry (1995) 38:330–335.
   PubMed Web of Science ®Google Scholar
• GERACIOTI TD, Jr., LOOSEN PT, ORTH DN: Low cerebrospinal fluid corticotropin releasing hormone concentrations in eucortisolemic depression. Biol. Psychiatry (1997) 42:166–174.
   Google Scholar
• HOLSBOER F: The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. j Psychiatric Res. (1999) 33:181–214.
   PubMed Web of Science ®Google Scholar
• ••Very thorough review of CRH antagonistsas antidepressants.
   Google Scholar
• MALKOWSKI SP, HANDANOS CM, DORIN RI: Localization of a negative glucocorticoid response element of the human corticotropin releasing hormone gene. Mal Cell Endocrine]. (1997) 127:189–199.
   PubMed Web of Science ®Google Scholar
• SAWCHENKO PE, SWANSON LW: The organization of noradrenergic pathways from the brainstem to the paraventricular and supraoptic nuclei in the rat. Brain Res. Rev. (1982) 4:275–325.
   Web of Science ®Google Scholar
• PLOTSKY PM: Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophyseal-portal circulation after activation of catecholaminergic pathways of central norpinephrine injection. Endocrinology (1987) 121:924–930.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM ET, SAWCHENKO PE: Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus. j Comp. Neural. (1988) 274:60–76.
   PubMed Web of Science ®Google Scholar
• KITAYAMA I, JANSON AM, CINTRA A et al.: Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain: evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla. j Neural Transm. (1988) 73:191–203.
   PubMed Web of Science ®Google Scholar
• PEPIN MC, BEAULIEU S, BARDEN N: Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res. Mal. Bran] Res. (1989) 6:77–83.
   PubMedGoogle Scholar
• BUDZISZEWSKA B, SIWANOWICZ J, PRZEGALISKI E: The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus. Poi j Pharmacy]. (1994) 46:147–152.
   Google Scholar
• BRADY LS, WHITFIELD HJ JR, FOX RJ, GOLD PW, HERKENHAM M: Long-term antidepressant administration alters corticotropin releasing hormone, tyrosine hydroxylase and mineralocorticoid receptor gene expression in rate brain. j Clin Invest. (1991) 87:831–837.
   PubMed Web of Science ®Google Scholar
• BRADY LS, GOLD PW, HERKENHAM M, LYNN AB, WHITFIELD HJ Jr.: The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Bran] Res. (1992) 572:117–125.
   Google Scholar
• CURTIS AL, VALENTINO RJ: Corticotropin-releasing factor neurotransmission in locus coeruleus: a possible site of antidepressant action. Brain Res. Bull. (1994) 35:581–587.
   PubMed Web of Science ®Google Scholar
• DELBENDE C, CONTESSE V, MOCAER E, KAMOUN A, VAUDRY H: The novel antidepressant, tianeptine, reduces stress-evoked stimulation of the hypothalamo-pituitary-adrenal axis. Eur. Pharmacy]. (1991) 202:391–396.
   PubMed Web of Science ®Google Scholar
• SKUTELLA T, PROBST JC, RENNER R, HOLSBOER F, BEHL C: Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience (1998) 85:795–805.
   PubMed Web of Science ®Google Scholar
• ••Antisense strategy probing the CRH1 receptor as an important mediator of anxiety.
   Google Scholar
• KOOB GF, GOLD LH: Molecular biological approaches in the behavioural pharmacology of anxiety and depression. Behav. Pharmacy]. (1997) 8:652.
   Google Scholar
• MOREAU JI, KILPATRICK G, JENCK F: Urocortin, a novel neuropeptide with anxiogenic-like properties. Neurareport (1997) 8:1697–1701.
   PubMed Web of Science ®Google Scholar
• SCHULZ DW, MANSBACH RS, SPROUSE J et al: CP-043,415, a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. USA (1996) 93:10477–10482.
   PubMed Web of Science ®Google Scholar
• ••Study of the effects of this Pfizer CRHantagonist in a rat model of anxiety, the acoustic startle response.
   Google Scholar
• LUNDKVIST J, CHAI Z, TEHERANIANR etal.: A non-peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur. Pharmacy]. (1996) 309:195–200.
   Google Scholar
• MANSBACH RS, BROOKS EN, CHEN YL: Antidepressant-like effects of CP-043,415, a selective CRF1 receptor antagonist. Eur. j Pharmacy]. (1997) 323:21–26.
   PubMed Web of Science ®Google Scholar
• KELLER PA, ELFCK L, GARNER J, MORGAN J, MCCLUSKEY A: Corticotropin releasing hormone: therapeutic implications and medicinal chemistry developments. Bioarg. Med. Chem. (2000) 8:1213–1223.
   PubMedGoogle Scholar
• ••Review of CRH receptors as antidepressanttargets.
   Google Scholar
• SAPOLSKY RM: The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biel Psychiatry (2000) 48:755–765.
   PubMed Web of Science ®Google Scholar
• ••Thorough review of the phenomenon ofhippocampal neurotoxicity in depression.
   Google Scholar
• DUMAN RS, MALBERG J, NAKAGAWA S, D'SA C: Neuronal plasticity and survival in mood disorders. Biol. Psychiatry (2000) 48:732–739.
   PubMed Web of Science ®Google Scholar
• ••Reviews neuronal plasticity in hippocampus, with particular attention to the effects of brain derived neurotrophic factor.
   Google Scholar
• VON GUNTEN A, FOX NC, CIPOLOTTI L, RON MA: A volumetric study of hippocampus and amygdala in depressed patients with subjective memory problems. I Neuropsychiatry Clin Neurosci. (2000) 12:493–498.
   PubMedGoogle Scholar
• SKOLNICK P: Antidepressants for the new millennium. Eur. j Pharmacy]. (1999) 375:31–40.
   PubMed Web of Science ®Google Scholar
• ••Extensive review of NMDA receptors asantidepressant targets.
   Google Scholar
• TRULLAS R, SKOLNICK P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. Pharmacy]. (1990) 185:1–10.
   PubMed Web of Science ®Google Scholar
• PAPP M, MORYL E: Similar effects of chronic treatment with imipramine and the NMDA antagonists CGP37849 and MK-801 in a chronic mild stress model of depression in rats. Eur. Neuropsychapharmacal (1993) 3:348–349.
   Google Scholar
• ••This study demonstrated similaritiesbetween the antidepressants and NMDA antagonists in the chronic mild stress model of depression in rats.
   Google Scholar
• PAPP M, MORYL E: Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. Pharmacol (1994) 263:1–7.
   PubMed Web of Science ®Google Scholar
• PAPP M, MORYL E: Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and d-cycloserine in an animal model of depression. Eur. j Pharmacol (1996) 316:145–151.
   PubMedGoogle Scholar
• KRYSTAL JH, D'SOUZA DC, PETRAKIS IL et al.: NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harvard Rev Psychiatry (1994) 7:125–143.
   Google Scholar
• ••Review of NMDA as a possibleantidepressant target.
   Google Scholar
• WILLNER PA: Validity, reliability and utility of the chronic mild stress model of depression: a 10 year review and evaluation. Psychopharmacol (1997) 134:319–329.
   Google Scholar
• KORNHUBER J, WELLER M: Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry (1997) 41:135–344.
   PubMed Web of Science ®Google Scholar
• PARSONS CG, DANYSZ W, QUACK G: Memantine is a clinically well tolerated N methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology (1997) 38:735–767.
   Google Scholar
• EVONIUK GE, HERTZMAN SKOLNICKP: A rapid method for evaluating the behavioral effects of phencyclidine-like dissociative anesthetics in mice. Psychopharmacology (1991) 105:125–128.
   PubMedGoogle Scholar
• CHERKOFSKY SC: 1- Aminocyclopropane-carboxylic acid; mouse to man interspecies pharmacokinetic comparisons and allometric relationships. Pharm. Science (1995) 84:1231–1235.
   PubMedGoogle Scholar
• Nowak G, Trullas R, Layer RT et al: Adaptive changes in the Nmethyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. Pharmacol Exp. Ther. (1993) 265:1380–1386.
   PubMed Web of Science ®Google Scholar
• ••Apparent indirect actions of theantidepressant imipramine on NMDA receptors.
   Google Scholar
• BRAUNER-OSBORNE H, EGEBJERG J, NIELSEN EO, MADSEN U, KROGSGAARD-LARSEN P: Ligands for glutamate receptors: design and therapeutic prospects. j Med. Chem. (2000) 43:2609–2645.
   PubMed Web of Science ®Google Scholar
• LEHMANN J, SCHNEIDER J, MCPHERSON S etal.: CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo. J. Pharmaca. Exp. Ther. (1987) 240:737–746.
   Google Scholar
• PALMER GC, WIDZOWSKI D: Low affinity use-dependent NMDA receptor antagonists show promise for clinical development. Amino Acids (2000) 19:151–155.
   PubMedGoogle Scholar
• ••Discussion of possible therapeutic uses ofNMDA receptor antagonists.
   Google Scholar
• ROGAWSKI MA: Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability. Amino Acids (2000) 19:133–149.
   PubMed Web of Science ®Google Scholar
• AIZENMAN E, POTTHOFF WK: Lack of interaction between nitric oxide and the redox modulatory site of the NMDA receptor. Br j Pharmacol (1999) 126(1):296–300.
   PubMedGoogle Scholar
• ••A study to discover the mechanisms bywhich nitric oxide regulates NMDA receptors.
   Google Scholar
• MILHAUD D, FAGNI L, BOCKAERT J, LAFON-CAZAL M: Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures. Neuropharmacol (2000) 39(12):2244–2254.
   PubMedGoogle Scholar
• LEROY V, MAUSER P, GAO Z, PEET NP: Neurokinin receptor antagonists. Expert Opin. Investig. Drugs (2000) 9:735–746.
   PubMed Web of Science ®Google Scholar
• ••Thorough review of NK antagonists.
   Google Scholar
• HOKFELT T. PERNOW B. WAHREN J: Substance P: a pioneer amongst neuropeptides. j Intern. Med. (2001) 249:27–40.
   PubMed Web of Science ®Google Scholar
• ••Review of the NK substance P, with specialattention toward the potential therapeutic effects of antagonists.
   Google Scholar
• RIBERIO SJ, TEXEIRA RIVI, CALIXTO JB, DELIMA TCM: Tachykinin NK3 receptor involvement in anxiety. Neuropeptides (1999) 33:181–188.
   PubMedGoogle Scholar
• MASSI M, PANOCKA I, DE CARO G: The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides. (2000) 21:1597–1609.
   PubMed Web of Science ®Google Scholar
• PAPP M, VASSOUT A, GENTSCH C: The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav. Brain Res. (2000) 115:19–23.
   PubMed Web of Science ®Google Scholar
• RUPNIAK NM, CARLSON EC, HARRISON T et al: Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology. (2000) 39:1413–1421.
   PubMed Web of Science ®Google Scholar
• FILE SE: Anxiolytic action of a neurokininlreceptor antagonist in the social interaction test. Pharmacol Biochem. Behav. (1997) 58:747–752.
   PubMedGoogle Scholar
• KRAMER MS, CUTLER N, FEIGHNER J et al: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281:1640–1645.
   PubMed Web of Science ®Google Scholar
• ••This paper was the first demonstration ofthe potential effectiveness of Substance P antagonism in depression.
   Google Scholar
• ENSERINK M: Can the placebo be the cure? Science (1999) 284:238–240.
   PubMed Web of Science ®Google Scholar
• LANE R: Placebo response to antidepressants. German I Psychiatry (1999) 2:1–11.
   Google Scholar
• ••Good review discussing commonmisconceptions about placebo response in depression research.
   Google Scholar
• LOWE JA III.: Nonpeptide tachykinin antagonists: medicinal chemistry and molecular biology. Medicinal Res. Rev (1996) 16:527–545.
   PubMedGoogle Scholar
• ••Lengthy review of NK antagonists.
   Google Scholar
• SEWARD EM, SWAIN CJ: Neurokinin receptor antagonists. Expert Opin. Ther. Patents (1999) 9:571–582.
   Web of Science ®Google Scholar
• ••Review of NK receptor antagonists andpossible therapeutic effects.
   Google Scholar
• SWAIN C, RUPNIAK NMJ: Progress in the development of neurokinin antagonists. Ann Rep. Med. Chem. (1999) 34:51–60.
   Google Scholar
• GAO Z, PEET NP: Recent advances in neurokinin receptor antagonists. Curr. Med. Chem. (1999) 6:375–388.
   PubMed Web of Science ®Google Scholar
• BILLINGTON CJ, BRIGGS JE, HARKER S, GRACE M, LEVINE AS: Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am. Physiol (1994) 266\(Suppl. 35): R1765–R1770.
   Google Scholar
• ••Review of the role of NPY in food intakeand energy expenditure.
   Google Scholar
• MAKINO S, BAKER RA, SMITH MA, GOLD PW: Differential regulation of neuropeptide YmRNA expression in the arcuate nucleus and locus coeruleus by stress and antidepressants. j Ern/au-Mal (2000) 12:387-395. Expert Opin. Ther. Patents (2001) 11(11)1709
   Google Scholar
• STANLEY B, LEIBOWITZ S: Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. Proc. Natl. Acad. Sri. USA (1985) 82:3940–3943.
   PubMed Web of Science ®Google Scholar
• DALLMAN ME STRACK AM, AKANA SF et al.: Feast and famine: critical role of glucocorticoids. Front Neuroendocrinol (1993) 14:303–347.
   Google Scholar
• MUNCK A, GUYRE PM, HOLBROOK NJ: Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocrine (1984) 5::25–44.
   Google Scholar
• BAKER RA, HERKENHAM M, BRADY LS: Effects of long-term treatment with antidepressant drugs on proopiomelanocortin and neuropeptide Y mRNA expression in the hypothalamic arcuate nucleus of rats. j Neuroendocrinol. (1996) 5: 337–343.
   Google Scholar
• WIEDERLOV E, LINDSTROM LH, WAHLESTEDT C, EWAN R: Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. Psychiatric Res. (1988) 22:69–79.
   Google Scholar
• GJERRIS A, WIDERLOV E, WERDELIN L, EWAN R: Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls. Psychiatry Neurosci. (1992) 17:23–27.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO H, ONISHI H, KOIDE S, KAI T, YAMAGAMI S: Plasma neuropeptide Y in patients with major depressive disorder. Neuroscifett. (1996) 216(1):57–60.
   PubMed Web of Science ®Google Scholar
• WIDOWSON PS, ORDWAY GA, HALARIS AE: Reduced neuropeptide Y concentrations in suicide brain. _J. Neurocliem. (1992) 59(1):73–80.
   PubMedGoogle Scholar
• HEILIG M, KOOB GE EKMAN R, BRITTON KT: corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci. (1994) 17:80–85.
   PubMed Web of Science ®Google Scholar
• SONG C, EARLEY B, LEONARD BE: The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression. Brain Behav. Immurrio, (1996) 10(1):1–16.
   PubMedGoogle Scholar
• STOGNER KA, HOLMES PV: Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. Pharmacol. (2000) 387(2):R9–10.
   Web of Science ®Google Scholar
• ••This study suggests that NPY1 agonists may have antidepressant effects.
   Google Scholar
• MATHE AA: Neuropeptides and electroconvulsive treatment. j ECT (1998) 15(1):60–75.
   Google Scholar
• KASK A, RAGO L, HARRO J: Anxiogenic-like effect of the neuropeptide Y Y-1 receptor antagonist BIBP3226: antagonism with diazepam. Eur. Pharmacol. (1996) 317:R3–R4.
   Google Scholar
• KASK A, RAGO L, HARRO J: a-Helical CRF9-41 prevents anxiogenic-like effect of NPY Y-1 receptor antagonist BIBP3226 in rats. Neuroreport (1997) 8:3645–3647.
   PubMed Web of Science ®Google Scholar
• WAHLESTEDT C, REIS DJ: Neuropeptide Y-related peptides and their receptors-are the receptors potential therapeutic drug targets? Ann. Rev. Pharmacol. Toxicol. (1993) 33:309–352.
   PubMedGoogle Scholar
• KASK A, VASAR E, HEIDMETS LT, ALLIKMETS L, WIKBERG JE: Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur. Pharmacol. (2001) 414:(2-3):215–224.
   PubMedGoogle Scholar
• ENSERINCK M: Can the placebo be the cure? Science (1999) 284:238–240.
   Google Scholar
• MICHELS KB: The placebo problem remains. Arch. Cm. Psychiatry (2000) 57:321–322.
   PubMedGoogle Scholar
• QUITKIN FM, KLEIN DF: What conditions are necessary to assess antidepressant efficacy? Arch. Gen. Psychiatry (2000) 57:323–324.
   Google Scholar
• ••Excellent discussion of critical methods inantidepressant clinical trials, with particular attention to the placebo effect.
   Google Scholar
• HAMBURG SR: Antidepressants are not placebos. Am. Psychologist (2000) 55:761–762.
   PubMedGoogle Scholar
• ••This paper effectively debunks the notionthat antidepressants are merely acting as placebos.
   Google Scholar
• ANDREWS G: Placebo response in depression: bane of research, boon to therapy. Br. J. Psychiatry (2001) 178:192–194.
   PubMed Web of Science ®Google Scholar
• MONCRIEF J, WESSELY S, HARDY R: Meta-analysis of trials comparing antidepressants with active placebos. Br. Psychiatry (1998) 172: 227–231.
   PubMedGoogle Scholar
• KESSLER RC, MCGONAGLE KA, ZHAO S etal.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8–19.
   Google Scholar
• ••Significant paper on the epidemiology of psychiatric illnesses.
   Google Scholar
• SHELTON RC, BROWN L: Mechanisms of action in the treatment of anxiety. J .0177. Psychiatry (In Press).
   Google Scholar
• CLARK LA, WATSON D: Tripartite model of anxiety and depression: Psychometric evidence and taxonomic implications. Abriorm. Psycho]. (1991) 100:316–336.
   PubMed Web of Science ®Google Scholar
• WATSON D, WEBER K, ASSENHEIMER JS et al.: Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom subscales. Abriorm. Psycho]. (1995) 1:3–14.
   Google Scholar
• WATSON D, CLARK LA, WEBER K, ASSENHEIMER JS, STRAUSS ME, MCCORMICK: Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. j Abriorm. Psycho]. (1995) 104: 15–25.
   Google Scholar
• WILLNER P Animal models of depression: an overview. Pharmacol. Therapeutics (1990)45:425–55.
   PubMed Web of Science ®Google Scholar
• ••Thorough review of this topic.
   Google Scholar
• WILLNER P: Animal models as simulations of depression. Trends Pharm. Li. (1991) 12:131–136.
   PubMed Web of Science ®Google Scholar
• WILLNER P: Animal models of depression: validity and applications. Adv. Biochem. Psychopharmacol. (1995) 49:19–41.
   PubMedGoogle Scholar
• TAYLOR KM: Comparison of the antihistaminic effect of burimamide and mepyramine and their effect on the activity of histamine methyltransferase. Biochem Pharmacol. (1973) 22:2775–2776.
   PubMedGoogle Scholar
• PRZEGALINSKI E, MORYL E, PAPP M: The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression. Neuropharmacology (1995) 34:1305–1310.
   PubMedGoogle Scholar